ESKAPE bacteria are a major global threat due to their rapid antibiotic resistance acquisition and severe healthcare-associated infections. Effective countermeasures require epidemiological surveillance and resistance transmission studies, particularly for antimicrobial-resistant (AMR) colonization in intensive care unit (ICU) patients. Whole-genome sequencing (WGS) provides critical information on resistance spread and mechanisms. In the provided protocol, rectal and oropharyngeal swabs, or endotracheal aspirate/bronchoalveolar lavage for intubated patients, are collected at ICU admission and twice weekly. Patient interviews and medical records identify risk factors for resistant microflora. Samples undergo cultivation, species identification, antibiotic susceptibility testing, and DNA extraction. Sequencing is performed using second- and third-generation platforms, with selected isolates subject to hybrid genome assembly. Resistance genes, virulence factors, and typing profiles (MLST, cgMLST) are determined. This protocol characterizes the ICU patient colonization by AMR pathogens, including species distribution, phenotypic and genotypic resistance profiles, clonal structure, and temporal changes. It estimates detection frequency and colonization patterns at each locus, identifies key risk factors, including prior community or inter-facility exposure, and analyzes associations between risk factors and admission colonization. The study aims to estimate AMR infection risk and severity in ICU patients through the comprehensive analysis of colonization dynamics, resistance patterns, and clonal characteristics using WGS data on pathogen composition and AMR trends.
Background/Objectives: The global spread of multidrug-resistant pathogens complicates the treatment of ventilator-associated pneumonia (VAP), causing significant hospi-tal-acquired morbidity and mortality. This study was designed to evaluate the efficacy and safety of the non-traditional antibacterial drug Fluorothiazinone (FT) to prevent VAP caused by Gram-negative bacteria in patients on mechanical ventilation. Methods: We conducted a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial at 14 hospitals in Moscow and St. Petersburg. Treatment arm patients received FT at a dose: 2400 mg/day for the first 2 days and 1800 mg/day from the third day and further (but no more than 14 days) until the occurrence of VAP caused by gram-negative bacteria, confirmed clinically and microbiologically, or until the participant completed the study for other reasons. Results: Statistically significant differences were observed between the FT and placebo groups in the proportion of patients without clinically and microbiologically confirmed VAP caused by Gram-negative bacteria that developed 72-120 hours after tracheal intuba-tion and initiation of mechanical ventilation, as well as throughout the entire treatment period. Treatment with FT was associated with a 56% reduction in the risk of developing VAP, following adjustment for relevant clinical and demographic variables. Safety out-comes in the group receiving the study drug FT were not different from those in the place-bo group. Conclusions: The possibility of antibacterial prophylaxis with FT, to which resistance does not develop, which has a broad spectrum of action, a high degree of tissue distribu-tion, and a favorable safety profile, was demonstrated.
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a critical public health threat because infections caused by this pathogen are associated with high morbidity, mortality, and limited effective therapeutic options. Whilst the majority of studies have concentrated on inter-patient bacterial transmission, within-host genomic analysis offers unprecedented resolution for tracking dynamic clone predominance, plasmid rearrangements, and microevolution under clinical selection pressures. Methods and Results: Whole-genome sequencing (WGS) of nine isolates recovered from oral and rectal swabs revealed an exceptional case of CRKP clonal turnover in an intensive care unit (ICU) patient. Three distinct high-risk clones were identified during the 18 days of surveillance: an initial ST101 (Clonal Group (CG) 101) strain (days 1–7) followed by concurrent colonization with ST395 (carrying blaNDM-5) and ST512 lineages (both CG258, days 11–18). Conclusions: This study describes a rare instance of within-host heterogeneity of CRKP, involving three distinct STs spanning two CGs. Whole-genome analysis revealed potential structural rearrangements of resistance- and virulence-associated plasmids between coexisting lineages. These genomic shifts likely reflect rapid adaptation under the intense selective pressure of broad-spectrum antibiotic therapy, culminating in the persistence of a less virulent yet multidrug-resistant ST512 clone and a favorable clinical outcome with patient recovery.